Mwyngil Therapeutics Licenses GPR75 Modulators for Novel Obesity and Diabetes Treatment Approach
Key Insights
Mwyngil Therapeutics (search) has in-licensed GPR75 (search) reverse agonist molecules from Expert Systems Inc. (search), targeting a novel pathway for obesity (search) and type 2 diabetes (search) treatment.
The GPR75 (search) modulators demonstrated low-nanomolar potency and significant weight reduction in preclinical diet-induced obesity (search) models while preserving lean body mass.
The licensing agreement expands Mwyngil's cardiometabolic portfolio and creates potential synergies with their existing NLRP3 (search) inflammasome inhibitor programs.
Mwyngil Therapeutics (search) Inc. announced on November 6, 2025, the in-licensing of several lead GPR75 (search) modulator molecules and a proprietary cell-surface discovery platform from Expert Systems Inc. (search), marking a significant expansion into novel cardiometabolic therapeutics. The collaboration strengthens Mwyngil's portfolio in addressing obesity (search), type 2 diabetes (search), and chronic inflammatory conditions through a first-in-class approach targeting the orphan G-protein-coupled receptor GPR75.
Novel Therapeutic Target with Genetic Validation
GPR75 (search) represents an orphan G-protein-coupled receptor expressed across multiple metabolically active tissues, including hypothalamic neurons, adipose tissue, liver, kidney, and vascular endothelium. Human genetic studies have established a compelling therapeutic rationale, demonstrating that loss-of-function variants of GPR75 correlate with lower body-mass index (BMI), enhanced insulin sensitivity, and protection from obesity (search) and type 2 diabetes (search).
The licensed GPR75 reverse agonists (search) are designed to actively suppress baseline receptor signaling, effectively reproducing these protective genetic phenotypes through pharmacological intervention. This approach offers a novel, disease-modifying small-molecule strategy for addressing metabolic disorders at their root cause.
Promising Preclinical Results
In preclinical studies, Mwyngil's newly licensed GPR75 reverse agonists (search) demonstrated several favorable characteristics that support their therapeutic potential. The compounds exhibited low-nanomolar potency and high target selectivity in vitro, indicating precise receptor engagement without significant off-target effects.
The molecules showed good oral bioavailability compatible with once-daily dosing, a critical factor for patient compliance in chronic metabolic conditions. Additionally, the compounds displayed favorable ADME (absorption, distribution, metabolism, and excretion), safety, and tolerability profiles in preclinical assessments.
Most notably, the GPR75 reverse agonists (search) produced significant reduction in relative weight gain in diet-induced obesity (search) models over five weeks of daily oral dosing, while importantly sparing lean body mass. This selective effect on fat mass reduction represents a key advantage over conventional weight loss approaches that often compromise muscle mass.
Synergistic Therapeutic Approach
Tudor Oprea, MD, PhD, Chief Executive Officer of Expert Systems Inc. (search), emphasized the complementary nature of the collaboration, stating: "GPR75 reverse agonists (search) and Mwyngil's portfolio of brain-permeable and systemic NLRP3 inhibitors (search)—targeting obesity (search), cardiovascular, and chronic kidney diseases—jointly address the intertwined axes of metabolism and inflammation."
The combination approach targets multiple interconnected pathways:
Metabolic Benefits: GPR75 (search) reverse agonism enhances insulin sensitivity and weight control, while NLRP3 (search) inhibition reduces IL-1β/IL-18-driven insulin resistance, potentially producing amplified glycemic benefits.
Anti-inflammatory Effects: GPR75 (search) modulation down-regulates upstream inflammasome triggers, and NLRP3 (search) inhibition blocks inflammasome assembly, together yielding broad suppression of chronic inflammation.
Cardiovascular Protection: The combined approach aims to improve blood pressure, endothelial function, and plaque inflammation, potentially translating to reduced residual cardiovascular risk.
Renal Benefits: GPR75 (search) modulation may alleviate filtration stress, while NLRP3 (search) inhibition mitigates tubular injury, offering additive kidney protection.
Strategic Portfolio Expansion
The licensing agreement represents a strategic expansion of Mwyngil's therapeutic focus beyond their established inflammasome inhibitor programs. The company, headquartered in Dover, Delaware, and Boston, Massachusetts, has built expertise in developing brain-permeable and systemic inflammasome inhibitors, with existing partnerships including a 2025 collaboration with Brenig Therapeutics (search) for NLRP3 (search) inhibitor development in Parkinson's disease (search) and other neuroinflammatory indications.
Mwyngil plans to continue advancing the licensed GPR75 (search) candidates and related intellectual property within its cardiometabolic and chronic-inflammation franchise. The financial terms of the license agreement with Expert Systems Inc. (search) were not disclosed.
Expert Systems Inc. (search), the licensing partner, operates as a life-sciences accelerator with an AI/ML-enabled platform that integrates rational drug design, predictive pharmacology, and translational modeling. The company has supported over 30 R&D programs funded by institutional investors and strategic partners across North America, Europe, and Australia.